MEDITECH(SH:603990)2021-04-16 16:00Financial Performance - Operating revenue increased by 187.40% to CNY 47,093,244.80 compared to the same period last year[5] - Net profit attributable to shareholders was CNY 4,890,918.03, a significant recovery from a loss of CNY 17,397,120.67 in the previous year[5] - The company reported a basic earnings per share of CNY 0.04, recovering from a loss of CNY 0.11 per share in the previous year[7] - Revenue increased by CNY 30.71 million, a growth of 187.4%, mainly due to the recovery of operations to pre-pandemic levels and the consolidation of Haikou Mary Hospital's income[14] - Net profit for Q1 2021 was ¥7,929,049.10, compared to a net loss of ¥16,477,975.40 in Q1 2020, marking a turnaround in profitability[26] - The company's revenue for Q1 2021 reached ¥34,489,405.13, a significant increase of 196.5% compared to ¥11,608,748.61 in Q1 2020[28] Cash Flow - Cash flow from operating activities improved to a net outflow of CNY 13,196,761.79, compared to a larger outflow of CNY 19,172,443.55 in the same period last year[5] - Net cash flow from operating activities increased by CNY 5.98 million, driven by an increase of CNY 33.72 million in cash received from sales of goods and services compared to the same period last year[14] - Operating cash flow for Q1 2021 was negative at -¥13,196,761.79, an improvement from -¥19,172,443.55 in Q1 2020[31] - The cash inflow from operating activities was CNY 77,397,935.06, a 51.7% increase from CNY 51,005,829.75 in Q1 2020[34] - The net cash flow from operating activities was -CNY 1,797,672.97, an improvement from -CNY 6,856,776.43 in the same period last year[34] Assets and Liabilities - Total assets decreased by 10.55% to CNY 1,361,155,806.74 compared to the end of the previous year[5] - The company's total assets as of March 31, 2021, were ¥1,486,403,255.93, a decrease of 2.9% from ¥1,531,066,571.79 at the end of 2020[23] - Current assets totaled ¥1,062,725,146.95, down 13.1% from ¥1,222,338,242.75 at the end of 2020[23] - The total liabilities increased to ¥317,964,061.54, up from ¥303,058,756.33, reflecting a rise of 4.0%[23] - The company's equity decreased to ¥1,168,439,194.39 from ¥1,228,007,815.46, a decline of 4.9%[24] Investments and Acquisitions - The company acquired a 49% stake in Haikou Mary Hospital, impacting minority interests which decreased by 93.94%[13] - Investment activities generated a net cash outflow of CNY 433.09 million, mainly due to increased purchases of financial products and the acquisition of 49% equity in Haikou Mary Hospital[15] - The total investment cash outflow for Q1 2021 was ¥434,920,123.60, significantly higher than ¥46,862,939.59 in Q1 2020, reflecting aggressive investment strategies[32] Operating Costs and Expenses - Operating costs increased by CNY 6.35 million, a growth of 116.4%, primarily due to the increase in operating revenue[14] - Operating costs for Q1 2021 were ¥47,941,049.55, up from ¥39,960,895.44 in the same period last year, reflecting a year-over-year increase of 19.6%[24] - The company reported a total operating expenses of ¥30,294,431.28 in Q1 2021, up from ¥20,121,721.71 in Q1 2020, reflecting increased sales and management costs[28] Research and Development - Development expenses rose by 87.18% to CNY 1,146,780.00, mainly due to capitalized R&D costs for a new project[13] - Research and development expenses decreased by CNY 4.75 million, a reduction of 44.27%, due to the capitalization of R&D expenses related to a specific project[14] - Research and development expenses for Q1 2021 were ¥5,984,203.57, down 44.5% from ¥10,738,588.35 in Q1 2020[24] - Research and development expenses decreased to ¥1,730,670.40 in Q1 2021 from ¥8,189,283.64 in Q1 2020, indicating a strategic shift in resource allocation[28] Shareholder Information - The number of shareholders reached 12,006, indicating a stable shareholder base[9]